Eric Jordie

Eric Jordie leads a team of scientists that integrate chemical, biological, physiological, and pharmacological knowledge using advanced quantitative methods, including machine learning and AI. These techniques, often deployed through open-science technologies, inform and accelerate the discovery, development, and registration of life-changing therapies.

Eric has more than 25 years of experience in climate science and the biopharmaceutical industry, having held roles at NASA, GlaxoSmithKline, qPharmetra, Parexel, and Metrum Research Group. At NASA, he developed and validated complex models for biological and climate systems, earning multiple awards for scientific innovation.

During his tenure in the pharmaceutical industry, he contributed to numerous discovery and clinical development programs by implementing Model-Informed Drug Development (MIDD) strategies across a wide range of therapeutic areas, notably immunotherapies, oncology agents, and infectious diseases. MIDD approaches apply advanced analytics, pharmacometrics, systems pharmacology, and machine learning techniques to streamline drug development. Many of his MIDD strategies have led to successful commercial treatments and have advanced the application of MIDD techniques.

Eric holds B.S. and M.S. degrees in chemical engineering from Penn State, with a focus on computational turbulent fluid mechanics. He is dedicated to fostering innovation through collaboration and the growth of multicultural and multidisciplinary teams. His commitment to advancing integrative quantitative frameworks and efficient drug development strategies using open-science technologies drives his passion for developing transformative treatments.